Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Naftopidil - Asahi Kasei Pharma

Drug Profile

Naftopidil - Asahi Kasei Pharma

Alternative Names: Avishot; BM-15275; Eapidil; Flivas; KT-611; Naphtopidil

Latest Information Update: 11 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Asahi Kasei; Asahi Kasei Pharma Corp; Dong-A ST; MSD KK
  • Class Antihypertensives; Naphthalenes; Piperazines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Benign prostatic hyperplasia
  • Phase III Postoperative pain
  • No development reported Neurogenic bladder; Urinary calculi

Most Recent Events

  • 19 Jan 2018 No development reported - Phase-III for Urinary calculi in South Korea (PO)
  • 01 Aug 2015 Dong-A ST completes a phase III trial in Urinary calculi in South Korea (NCT01952314)
  • 01 May 2014 Phase-III clinical trials in Urinary calculi in South Korea (PO) (NCT01952314)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top